CA3090548C - COMPOSITIONS AND METHODS FOR PROVIDING HEMATOPOIETIC FUNCTION - Google Patents
COMPOSITIONS AND METHODS FOR PROVIDING HEMATOPOIETIC FUNCTIONInfo
- Publication number
- CA3090548C CA3090548C CA3090548A CA3090548A CA3090548C CA 3090548 C CA3090548 C CA 3090548C CA 3090548 A CA3090548 A CA 3090548A CA 3090548 A CA3090548 A CA 3090548A CA 3090548 C CA3090548 C CA 3090548C
- Authority
- CA
- Canada
- Prior art keywords
- cells
- expanded
- cord blood
- cell
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
- G16B30/10—Sequence alignment; Homology search
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/145—Thrombopoietin [TPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/42—Notch; Delta; Jagged; Serrate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/58—Adhesion molecules, e.g. ICAM, VCAM, CD18 (ligand), CD11 (ligand), CD49 (ligand)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Reproductive Health (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Evolutionary Biology (AREA)
- Theoretical Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pregnancy & Childbirth (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA3090548A CA3090548C (en) | 2010-04-09 | 2011-04-11 | COMPOSITIONS AND METHODS FOR PROVIDING HEMATOPOIETIC FUNCTION |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32257510P | 2010-04-09 | 2010-04-09 | |
| US61/322,575 | 2010-04-09 | ||
| CA3090548A CA3090548C (en) | 2010-04-09 | 2011-04-11 | COMPOSITIONS AND METHODS FOR PROVIDING HEMATOPOIETIC FUNCTION |
| CA2795938A CA2795938C (en) | 2010-04-09 | 2011-04-11 | Compositions and methods for providing hematopoietic function |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2795938A Division CA2795938C (en) | 2010-04-09 | 2011-04-11 | Compositions and methods for providing hematopoietic function |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3090548A1 CA3090548A1 (en) | 2011-10-13 |
| CA3090548C true CA3090548C (en) | 2025-09-02 |
Family
ID=44120971
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3090548A Active CA3090548C (en) | 2010-04-09 | 2011-04-11 | COMPOSITIONS AND METHODS FOR PROVIDING HEMATOPOIETIC FUNCTION |
| CA2795938A Active CA2795938C (en) | 2010-04-09 | 2011-04-11 | Compositions and methods for providing hematopoietic function |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2795938A Active CA2795938C (en) | 2010-04-09 | 2011-04-11 | Compositions and methods for providing hematopoietic function |
Country Status (5)
| Country | Link |
|---|---|
| US (4) | US20130095080A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3097916B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP2013523842A (cg-RX-API-DMAC7.html) |
| CA (2) | CA3090548C (cg-RX-API-DMAC7.html) |
| WO (1) | WO2011127472A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013086436A1 (en) | 2011-12-08 | 2013-06-13 | Fred Hutchinson Cancer Research Center | Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells |
| EP2864476A4 (en) * | 2012-06-14 | 2016-04-06 | Hutchinson Fred Cancer Res | EX-VIVO EXPANSION OF MYOGENIC STEM CELLS THROUGH NOTCH ACTIVATION |
| AU2014205662B2 (en) * | 2013-01-08 | 2019-09-05 | Fred Hutchinson Cancer Research Center | Compositions and methods for expansion of embryonic hematopoietic stem cells |
| US20160250258A1 (en) | 2013-10-31 | 2016-09-01 | Fred Hutchinson Cancer Research Center | Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof |
| US20150342165A1 (en) * | 2014-05-29 | 2015-12-03 | City Of Hope | Humanized mouse and methods of using the same |
| KR102382905B1 (ko) | 2014-06-04 | 2022-04-04 | 프레드 헛친슨 켄서 리서치 센터 | 노치 1 및/또는 노치 2 작용제를 사용한 줄기 세포의 확장 및 생착 |
| JP2016104711A (ja) * | 2014-11-21 | 2016-06-09 | 国立大学法人 東京大学 | 造血幹細胞移植を補助することに用いるための医薬組成物およびその製造方法 |
| US10350245B2 (en) | 2015-01-21 | 2019-07-16 | Fred Hutchinson Cancer Research Center | Point-of-care and/or portable platform for gene therapy |
| EP3288570A4 (en) | 2015-04-29 | 2018-11-21 | Fred Hutchinson Cancer Research Center | Modified stem cells and uses thereof |
| EP3288569A4 (en) | 2015-04-29 | 2018-12-19 | Fred Hutchinson Cancer Research Center | Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof |
| JP2018537472A (ja) * | 2015-12-04 | 2018-12-20 | フレッド ハッチンソン キャンサー リサーチ センター | 増殖造血幹細胞/前駆細胞集団の利用 |
| CA2968946A1 (en) * | 2016-05-30 | 2017-11-30 | Ottawa Heart Institute Research Corporation | Serum-free and xenogen-free human cardiac explant-derived stem cells and uses and methods for the production thereof |
| WO2018140532A1 (en) * | 2017-01-24 | 2018-08-02 | Fred Hutchinson Cancer Research Center | Systems and methods for hematopoietic cell expansion utilizing hydrogels |
| EP3849565A4 (en) | 2018-09-12 | 2022-12-28 | Fred Hutchinson Cancer Research Center | REDUCTION OF CD33 EXPRESSION TO SELECTIVELY PROTECT THERAPEUTIC CELLS |
| JP2022533191A (ja) * | 2019-05-17 | 2022-07-21 | デヴェラ セラピューティクス インコーポレイテッド | 拡大した幹細胞生成物を使用して、血液悪性腫瘍を有する患者の処置転帰を改善するための組成物および方法 |
| EP4476331A2 (en) | 2022-02-07 | 2024-12-18 | Ensoma, Inc. | Inhibitor-resistant mgmt modifications and modification of mgmt-encoding nucleic acids |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3753357A (en) | 1970-12-14 | 1973-08-21 | Ovitron Res Corp | Method and apparatus for the preservation of cells and tissues |
| US4199022A (en) | 1978-12-08 | 1980-04-22 | The United States Of America As Represented By The Department Of Energy | Method of freezing living cells and tissues with improved subsequent survival |
| US4559298A (en) | 1982-11-23 | 1985-12-17 | American National Red Cross | Cryopreservation of biological materials in a non-frozen or vitreous state |
| US5004681B1 (en) | 1987-11-12 | 2000-04-11 | Biocyte Corp | Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood |
| IE20030749A1 (en) | 1991-05-03 | 2003-11-12 | Indiana University Foundation | Human notch and delta binding domains in torporythmic proteins, and methods based thereon |
| IL101728A (en) | 1991-05-03 | 2007-08-19 | Univ Yale | Human Abandonment and Delta, Restrictive Areas of Effect in Tophoric Proteins, and Methods Based on Them |
| US5856441A (en) | 1991-05-03 | 1999-01-05 | Yale University | Serrate fragments and derivatives |
| US5869282A (en) | 1991-12-11 | 1999-02-09 | Imperial Cancer Research Technology, Ltd. | Nucleotide and protein sequences of the serrate gene and methods based thereon |
| WO1993012141A1 (en) | 1991-12-11 | 1993-06-24 | Yale University | Nucleotide and protein sequences of the serrate gene and methods based thereon |
| DK0861261T3 (da) | 1995-06-28 | 2009-12-14 | Imp Cancer Res Tech | Nukleotid- og proteinsekvenser af hvirveldyrs-Delta-gener og fremgangsmåder baseret derpå |
| US5780300A (en) | 1995-09-29 | 1998-07-14 | Yale University | Manipulation of non-terminally differentiated cells using the notch pathway |
| WO2002059285A1 (en) * | 2000-10-27 | 2002-08-01 | Fred Hutchinson Cancer Research Center | Methods for immortalizing cells |
| WO2003075789A2 (en) * | 2002-03-05 | 2003-09-18 | Richard Daniel D | Dual blood donation plus method |
| NZ566132A (en) * | 2003-02-13 | 2009-09-25 | Anthrogenesis Corp | Use of umbilical cord blood to treat inflammation, ParkinsonÆs disease or diabetes |
| US7569385B2 (en) * | 2003-08-14 | 2009-08-04 | The Regents Of The University Of California | Multipotent amniotic fetal stem cells |
| JP2005102656A (ja) * | 2003-10-02 | 2005-04-21 | Toray Ind Inc | 細胞培養器具およびそれを用いた細胞製剤の製造方法 |
| JP2007531116A (ja) * | 2004-03-26 | 2007-11-01 | セルジーン・コーポレーション | 幹細胞バンクを提供するためのシステム及び方法 |
| US7147626B2 (en) | 2004-09-23 | 2006-12-12 | Celgene Corporation | Cord blood and placenta collection kit |
| US8252587B2 (en) | 2004-10-25 | 2012-08-28 | Celerant Therapeutics, Inc. | Methods of expanding myeloid cell populations and uses thereof |
| AU2006252363A1 (en) * | 2005-06-02 | 2006-12-07 | Stemcyte, Inc. | Plasma-depleted, non-red blood cell-depleted cord blood compositions and methods of use |
| WO2007095594A2 (en) | 2006-02-14 | 2007-08-23 | Cellerant Therapeutics, Inc. | Methods and compositions for enhancing engraftment of hematopoietic stem cells |
-
2011
- 2011-04-11 EP EP16162911.8A patent/EP3097916B1/en active Active
- 2011-04-11 EP EP11717077A patent/EP2555781A1/en not_active Withdrawn
- 2011-04-11 CA CA3090548A patent/CA3090548C/en active Active
- 2011-04-11 US US13/640,298 patent/US20130095080A1/en not_active Abandoned
- 2011-04-11 JP JP2013504020A patent/JP2013523842A/ja active Pending
- 2011-04-11 CA CA2795938A patent/CA2795938C/en active Active
- 2011-04-11 WO PCT/US2011/031957 patent/WO2011127472A1/en not_active Ceased
-
2015
- 2015-07-16 US US14/801,771 patent/US20160199418A1/en not_active Abandoned
-
2017
- 2017-04-13 JP JP2017079812A patent/JP2017149752A/ja active Pending
-
2019
- 2019-10-01 US US16/590,255 patent/US20200030384A1/en not_active Abandoned
-
2020
- 2020-02-10 JP JP2020020612A patent/JP7041179B2/ja active Active
-
2024
- 2024-08-30 US US18/820,648 patent/US20250235488A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017149752A (ja) | 2017-08-31 |
| US20200030384A1 (en) | 2020-01-30 |
| EP3097916B1 (en) | 2021-07-07 |
| JP7041179B2 (ja) | 2022-03-23 |
| CA2795938A1 (en) | 2011-10-13 |
| US20130095080A1 (en) | 2013-04-18 |
| WO2011127472A1 (en) | 2011-10-13 |
| CA2795938C (en) | 2020-10-27 |
| CA3090548A1 (en) | 2011-10-13 |
| JP2013523842A (ja) | 2013-06-17 |
| EP2555781A1 (en) | 2013-02-13 |
| JP2020090529A (ja) | 2020-06-11 |
| US20250235488A1 (en) | 2025-07-24 |
| US20160199418A1 (en) | 2016-07-14 |
| EP3097916A1 (en) | 2016-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250235488A1 (en) | Compositions and methods for providing hematopoietic function | |
| EP3590520B1 (en) | Compositions for providing hematopoietic function without hla matching | |
| US10463698B2 (en) | Compositions and methods for expansion of embryonic hematopoietic stem cells | |
| ES2538305T3 (es) | Métodos para expandir poblaciones de células mieloides y usos de las mismas | |
| HK1231737A1 (en) | Compositions and methods for providing hematopoietic function without hla matching | |
| HK1231736B (en) | Compositions and methods for providing hematopoietic function | |
| HK1231736A1 (en) | Compositions and methods for providing hematopoietic function | |
| HK1231737B (en) | Compositions and methods for providing hematopoietic function without hla matching | |
| US20220218759A1 (en) | Compositions and methods for improving treatment outcomes for patients having hematological malignancies using an expanded stem cell product |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20200819 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D164 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: RESPONSE TO NOTICE OF ALLOWANCE Effective date: 20240822 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 14TH ANNIV.) - STANDARD Year of fee payment: 14 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250402 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250402 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT Effective date: 20250527 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250527 |
|
| Q17 | Modified document published |
Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q17-Q103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DOCUMENT PUBLISHED Effective date: 20250829 |
|
| F11 | Ip right granted following substantive examination |
Free format text: ST27 STATUS EVENT CODE: A-4-4-F10-F11-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: GRANT BY ISSUANCE Effective date: 20250902 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - STANDARD Year of fee payment: 15 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260224 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260224 |